Core Viewpoint - The announcement by Qingdao Blue Biological Co., Ltd. reveals the completion of the acquisition of a 50% stake in Aidi Meng Blue Biological Technology (Shandong) Co., Ltd. from ADM Singapore, marking a transition from international collaboration to full ownership by the company [1] Group 1: Acquisition Details - The acquisition price for the 50% stake is set at 47 million RMB, and following the transaction, Aidi Meng Blue will become a wholly-owned subsidiary of Qingdao Blue Biological [1][8] - The joint venture, which began in 2021, faced several challenges including project suspension and liquidation, ultimately leading to Qingdao Blue Biological's decision to acquire full control [1][5] Group 2: Historical Context - The partnership with ADM Singapore started with a shareholder agreement in October 2021, where both parties agreed to a 50% ownership structure through capital increase [5] - Subsequent announcements indicated the establishment of a project for the research and industrialization of micro-ecological preparations, with a total investment of approximately 400 million RMB [6][9] Group 3: Financial Status of the Target Company - Aidi Meng Blue reported a net loss of 3.69 million RMB for 2025, with total liabilities of 338,700 RMB and a net asset value of approximately 119.11 million RMB [8] - The construction of the micro-ecological preparation project has not commenced, and the company currently lacks substantial operational activities [8] Group 4: Company Performance - Qingdao Blue Biological achieved a revenue of 1.32 billion RMB in 2024, reflecting a year-on-year growth of 10.16%, with a net profit of approximately 62.64 million RMB [9] - The company invested 118 million RMB in research and development, accounting for 8.95% of its revenue, indicating a strong commitment to innovation within the industry [9][10] Group 5: Industry Position - Qingdao Blue Biological is recognized as one of the early entrants in the micro-ecological preparation sector in China, leveraging its research and sales channel development to establish a competitive advantage [10] - The company has developed a comprehensive technical innovation system, including a high-throughput screening and identification technology platform for microbial strains, positioning it as a leader in the field [10]

Core Insights - The news highlights significant corporate announcements and performance reports from various companies, indicating potential investment opportunities and market movements. Group 1: Corporate Announcements - Ge Weidong invested 1 billion yuan to subscribe for shares in Jianghuai Automobile's private placement, acquiring approximately 20.05 million shares at a price of 49.88 yuan per share, contributing to a total fundraising of about 3.5 billion yuan from eight investors [3][4] - *ST Cube completed its suspension review and will resume trading on February 11, 2026, after confirming no undisclosed significant matters related to the company [2] - Yunnan Baiyao plans to invest 137 million yuan in a second phase project for oral liquid production to meet growing market demand [11] Group 2: Performance Reports - Semiconductor manufacturer SMIC reported a 23.2% year-on-year increase in net profit for Q4 2025, reaching 1.223 billion yuan, driven by increased wafer sales and improved capacity utilization [5] - Special Biological Company reported a net profit of 1.038 billion yuan for 2025, reflecting a 25.39% increase year-on-year, attributed to stable sales of key products and new product approvals [6] - New Zobang achieved a net profit of 1.098 billion yuan in 2025, marking a 16.56% increase compared to the previous year [6] Group 3: Fundraising and Restructuring - New Han New Materials plans to raise up to 1 billion yuan through a private placement to fund projects related to high-performance resins and composite materials [8] - Chutian Long intends to raise up to 760 million yuan for the development of innovative safety products and digital operations [8] - Yi Yi Co. decided to terminate its plan to acquire 100% equity of a pet food company due to changes in the target company's operational conditions [8] Group 4: Major Contracts and Investments - Yunjiji Group signed an EPC contract worth 1.331 billion yuan for a cement production line and power station in Zimbabwe, representing 86.66% of the company's audited revenue for 2024 [9] - Solar Energy's subsidiary plans to acquire 100% of Jinhua Windling for 527 million yuan, enhancing its position in the solar power industry [9] - Yutong Technology intends to acquire 51% of Huayan Technology for 448.8 million yuan, which will become a subsidiary post-transaction [9]

Group 1: Company Announcements - Changfei Fiber currently does not engage in CPO-related business [1] - GCL-Poly Energy lacks production capacity for "space photovoltaic" products [1] - Zhongke High-tech plans to invest 145 million yuan in a new PCB drill pin project with an annual capacity of 30 million units [1] - Samsung Medical's wholly-owned subsidiary is expected to win a bid for a 321 million yuan project from Southern Power Grid [1] - Solar Energy's subsidiary intends to acquire 100% equity of Jinhua Windling [1] - SMIC expects a net profit of 1.223 billion yuan for Q4 2025, a year-on-year increase of 23.2% [2] - Kying Network has conducted its first buyback of 2.061 million shares [1] - Runbei Aerospace's controlling shareholder plans to reduce its stake by up to 3% [1] - Zhen'an Technology plans to raise no more than 740 million yuan through a private placement [1] - Jiangsu New Energy intends to issue convertible bonds to raise no more than 1.24 billion yuan [1] Group 2: Investment Projects - Kangda New Materials' subsidiary plans to invest in a project with an annual output of 30,000 tons of polyarylether [1] - China Shipbuilding Industry Corporation plans to build a comprehensive materials park [1] - Dong'a Ejiao intends to invest 1.485 billion yuan in a health consumer goods industrial park [1] - Hongda Co., Ltd. plans to invest approximately 71.43 million yuan in a 110kV power transmission and transformation project [1] Group 3: Share Buybacks and Reductions - Kying Network has executed its first buyback of 2.061 million shares [3] - Huasen Pharmaceutical's Liu Xiaoying plans to reduce her stake by up to 3% [3] - Wushang Group's Dazi Yintai plans to reduce its stake by up to 3% [3] - Runbei Aerospace's controlling shareholder plans to reduce its stake by up to 3% [3]

Group 1 - The company announced that its board of directors received a written resignation report from the securities affairs representative, Mr. You Shujun, who is resigning for personal reasons [2] - The resignation report will take effect from the date it is delivered to the company's board of directors [2]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

艾地盟蔚蓝生物科技(山东)有限公司 二〇二五年度 审计报告 致同会计师事务所 (特殊普通合伙) 费可使用手机"打一打"或进入"注册会计师行业统一监管平台（http://ac.mol.erv.cn）"进行了 一 e the state of the station of the status and the sta t 11: the state of " re . od 目 录 | 审计报告 | | | 1-3 | | --- | --- | --- | --- | | 公司资产负债表。 | - September 5 - 1 - | ﺎ ﻳﻜﻮﻥ ﺍﻟﻤﻌﺎﺭﻑ ﻭﺍﻟﻘ | 1-2 | | 公司利润表 | | | 3 | | 公司现金流量表 | | | 4 | | 公司股东权益变动表 | | | 5-6 | | 财务报表附注 | | | 7-29 | ornton 审计报告 致同审字（2026）第 371B000370 号 艾地盟蔚蓝生物科技(山东)有限公司董事会: 一、审计意见 我们审计了艾地盟蔚蓝生物科技（山东）有限公司（以下简称"艾地盟 蔚蓝公司")财务报表,包括 2025年 12月 31日的资产负 ...

青岛蔚蓝生物股份有限公司（以下简称"公司"）董事会于近日收到证券事 务代表游淑军先生提交的书面辞职报告，游淑军先生因个人原因申请辞去公司证 券事务代表职务，辞职报告自送达公司董事会之日起生效。 游淑军先生辞职后将不再担任公司任何职务。截至本公告披露日，游淑军先 生所负责的工作已完成交接，其辞职不会影响公司相关工作的开展。 公司董事会将根据《上海证券交易所股票上市规则》等相关规定，尽快聘任 符合任职资格的人员担任证券事务代表职务，协助公司董事会秘书开展相关工作。 特此公告。 青岛蔚蓝生物股份有限公司董事会 2026 年 2 月 11 日 证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-006 青岛蔚蓝生物股份有限公司 关于证券事务代表辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-004 青岛蔚蓝生物股份有限公司 关于全资子公司收购艾地盟蔚蓝生物科技（山东）有限公司 50%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 青岛蔚蓝生物股份有限公司（以下简称"公司"）全资子公司青岛蔚 蓝生物集团有限公司（以下简称"蔚蓝生物集团"）拟与 Archer Daniels Midland Singapore, Pte. Ltd.（以下简称"ADM Singapore"）签署《股权 转让协议》，由蔚蓝生物集团向 ADM Singapore 购买其持有的艾地盟蔚蓝生物 科技（山东）有限公司（以下简称"艾地盟蔚蓝"）50%股权，交易价格为人 民币 4,700.00 万元。 本次交易经公司第五届董事会第二十三次会议审议通过，本次交易尚需 提交股东会审议。 本次交易尚需公司股东会审议，能否获得批准存在不确定性。同时，本 次交易的交割完成需满足协议约定的多项先决条件，任何一项条件未能满足均可 能导致交割延迟或交易失败,敬请投资者注意投资 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-005 青岛蔚蓝生物股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开的日期时间：2026 年 3 月 6 日 14 点 30 分 召开地点：青岛市崂山区九水东路 596-1 号蔚蓝生物创新园 B 座多媒体会议 室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 股东会召开日期：2026年3月6日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 (一) 股东会类型和届次 2026年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 网络投票起止时间：自2026 年 3 月 6 日 至2026 年 3 月 6 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-003 青岛蔚蓝生物股份有限公司 关于公司第五届董事会第二十三次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 具体内容详见公司在上海证券交易所网站（www.sse.com.cn）披露的《青岛 蔚蓝生物股份有限公司关于全资子公司收购艾地盟蔚蓝生物科技（山东）有限公 司 50%股权的公告》（公告编号：2026-004）。 表决票：6 票，赞成票：6 票，反对票：0 票，弃权票：0 票。 2、审议并通过《关于召开公司 2026 年第一次临时股东会的议案》 公司拟于 2026 年 3 月 6 日召开 2026 年第一次临时股东会，具体时间、地点 及会议议题见公司同日披露的《青岛蔚蓝生物股份有限公司关于召开 2026 年第 一次临时股东会的通知》的公告（公告编号：2026-005）。 表决票：6 票，赞成票：6 票，反对票：0 票，弃权票：0 票。 特此公告。 青岛蔚蓝生物股份有限公司董事会 青岛蔚蓝生物股份有限公司（以下简称"公司 ...